Spironolactone inhibits the transcardiac extraction of aldosterone in patients with congestive heart failure
Takayoshi Tsutamoto, MDa,
Atsuyuki Wada, MDa,
Keiko Maeda, MDa,
Naoko Mabuchi, MDa,
Masaru Hayashi, MDa,
Takashi Tsutsui, MDa,
Masato Ohnishi, MDa,
Masahide Sawaki, MDa,
Masanori Fujii, MDa,
Takehiro Matsumoto, MDa,
Hajime Horie, MDa,
Yoshihisa Sugimoto, MDa and
Masahiko Kinoshita, MDa
a First Department of Internal Medicine, Shiga University of Medical Science, Tsukinowa, Seta, Otsu, Japan
View larger version (19K):
[in a new window]
|
Figure 1 Plasma aldosterone (ALDO) concentrations in the aortic root (AO) and coronary sinus (CS) in normal subjects.
|
|
View larger version (18K):
[in a new window]
|
Figure 2 Plasma aldosterone (ALDO) concentrations in the aortic root (AO) and coronary sinus (CS) in patients with congestive heart failure (CHF). Left panel shows data of ALDO in 96 CHF patients who did not receive spironolactone; right panel shows data of ALDO in 17 CHF patients who received spironolactone. *, p < 0.0001 vs. the value of AO.
|
|
View larger version (20K):
[in a new window]
|
Figure 3 Correlation between left ventricular end-diastolic volume index (LVEDVI) and the plasma levels of aldosterone (ALDO) in the aortic root (AO) and the transcardiac gradient of plasma ALDO in patients with congestive heart failure. AO = aortic root; CS = coronary sinus.
|
|
View larger version (22K):
[in a new window]
|
Figure 4 Correlation between the transcardiac gradient of plasma ALDO and the plasma levels of procollagen type III aminoterminal peptide (PIIINP) in coronary sinus (CS) in patients with congestive heart failure. AO = aortic root; CS = coronary sinus.
|
|
View larger version (23K):
[in a new window]
|
Figure 5 Correlation between the plasma aldosterone (ALDO) level in the aortic root (AO) and the transcardiac gradient of plasma ALDO in 96 patients with congestive heart failure (CHF) who did not receive spironolactone. AO = aortic root; CS = coronary sinus. Open circles represent 96 CHF patients who did not receive spironolactone; closed circles represent 17 CHF patients who received spironolactone.
|
|
|
